Insmed (INSM) said late Tuesday it will discontinue its development program of brensocatib in hidradenitis suppurativa, a skin disease, after its mid-stage trial failed to meet its targets.
The company said the drug candidate did not meet its primary or secondary efficacy endpoints in the phase 2b CEDAR study in either the 10 mg or 40 mg treatment arms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments